| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
New tests launched in August
New Tests
In August 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in August 2021 by Mayo Clinic Laboratories:
XHIM | X-Linked Hyper IgM Syndrome, Blood
This test is intended for screening for X-linked hyper-IgM (XL-HIGM) or CD40L deficiency, primarily in male patients younger than 10 years of age.
CIFA | Cutaneous Immunofluorescence Antibodies, IgA, Serum
This test is intended for confirming a diagnosis of pemphigoid, pemphigus, epidermolysis bullosa acquisita, or bullous lupus erythematosusma.
This test is intended in monitoring a previously confirmed diagnosis of B-cell lymphoblastic leukemia.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:
New tests launched in July
New Tests
In July 2021, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in July 2021 by Mayo Clinic Laboratories:
PTRIP | Prostate Triple (P63/KRT/P504S), Technical Component Only
This test is intended for use as an aid in identifying high-grade prostatic intraepithelial neoplasia and prostate cancer
P504S | Immunostain, Technical Component Only
This test is intended for use of characterization of renal cell carcinoma and the identification of high-grade prostatic intraepithelial neoplasia and prostate carcinoma.
SSX18 | Synovial Sarcoma Panel, Technical Component Only
This test is intended for aiding in distinguishing synovial sarcomas from similar sarcomas.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories:
